Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma in Situ × Cystoscopy × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2 Urinary Bladder Diseases 1 Carcinoma in Situ 1

Interventions

valrubicin 2 Gemcitabine 2 enfortumab vedotin 1 durvalumab 1 advexin 1 Surveys and Questionnaires 1 Standard of Care 1 Oncolytic Virotherapy 1 Nivolumab 1 Mitomycin 1 Interferons 1 Cystoscopy 1 Biopsy 1 ALT-801 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated

17 enrolled 9 charts

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon ⚡